Carvykti denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Carvykti as Not FDA-Approved

A "not FDA-approved" denial for Carvykti (ciltacabtagene autoleucel) from Aetna is almost always either an administrative error or a claim that the specific use requested falls outside Carvykti's approved indication. Carvykti holds FDA Biologics License Application (BLA) approval; a blanket claim that it is not FDA-approved for its indicated use is factually incorrect and straightforwardly disputable. However, if the denial reflects an off-label use argument — that the patient's line of therapy, diagnosis subtype, or other clinical characteristic does not match the approved indication — the rebuttal is more nuanced and requires precise documentation.

## Why This Denial Is Appealable

For on-label use: attach the FDA BLA approval letter and the current Carvykti prescribing information (available at Drugs@FDA) and confirm your case matches the stated indication. This is typically dispositive at the internal appeal level. For off-label use: while more complex, off-label use of an FDA-approved therapy may still be covered under many plans when supported by authoritative clinical evidence. Under ACA §2719 external review rules, IROs must consider whether a treatment is supported by recognized medical literature even when used off-label. Your oncologist should provide a comprehensive literature support letter.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 or state insurance law, file your internal appeal within the deadline stated in your denial letter. Attach FDA documentation as your primary exhibit.
• External review: Under ACA §2719, after a final internal denial you may request external review within approximately four months. IROs are equipped to evaluate FDA approval status and off-label evidence independently.
• Expedited review: Request simultaneously given the serious underlying condition; typical expedited turnaround is 72 hours.

## Documentation to Gather

• FDA BLA approval documentation: The Carvykti BLA approval letter and current prescribing information from Drugs@FDA. Highlight the exact approved indication language.
• Indication-matching documentation: A letter from your oncologist confirming the patient meets the approved indication as stated in the prescribing information, with supporting records (prior-therapy table, current disease-status labs, biopsy).
• Aetna clinical policy: Request the current Carvykti clinical policy bulletin. Note whether it was last updated before or after the FDA approval date — a stale policy is a ground for appeal.
• If off-label: Your oncologist should cite the applicable NCCN guideline category and any other recognized clinical authority supporting the use, without citing specific statistics — direct Aetna to verify those in current published sources.
• Diagnosis and treatment history: Full chart documentation supporting eligibility.

## Criteria-Mapping Structure

Build a direct rebuttal table: left column states Aetna's basis for the not-FDA-approved denial (quote from the denial letter); right column provides the documentary rebuttal with exhibit references. For on-label use, the table needs only one row — the FDA approval exhibit resolves the dispute. For off-label use, expand the table to cover each criterion in Aetna's clinical policy and the corresponding clinical evidence. Label every exhibit clearly so the reviewer can locate supporting documents without delay.